Siren Biotechnology Reveals SRN-101 as Lead Asset for High-Grade Gliomas with Both Orphan Drug and Rare Pediatric Disease Designations from the FDA Siren Biotechnology reveals SRN-101 as lead asset for high-grade gliomas with both Orphan Drug and Rare Pediatric Disease Designations from the FDA

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer

Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM) Siren Biotechnology Awarded $4M in Grant Funding from the California Institute for Regenerative Medicine (CIRM)

Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy™ for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy Data demonstrated that AAV vectors expressing engineered immunomodulatory interferon (IFN) cytokine payloads led to: Rapid and selective reduction in tumor size in high-grade glioma (HGG)...

Siren Biotechnology Launches to Pioneer Universal AAV Immuno-Gene Therapy™ for Cancer Novel approach combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single transformative modalityBelieved to be the first ever AAV...